Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Tremfya® (guselkumab) – New indication
September 11, 2024 - J&J announced the FDA approval of Tremfya (guselkumab), for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
